Clinical Trials Logo

CD30-positive Solid Tumor clinical trials

View clinical trials related to CD30-positive Solid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT02780011 Withdrawn - Clinical trials for CD30-positive Solid Tumor

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

AD3LE
Start date: December 2015
Phase: Phase 1
Study type: Interventional

This is an open label phase I trial designed to evaluate the maximum tolerated dose, dose-limiting toxicities, pharmacokinetics, and activity of the combination of alsertib (MLN8237) and brentuximab vedotin in patients with relapsed/refractory CD30-positive lymphomas and solid malignancies. Cohorts of 3-6 patients will receive escalating or de-escalating doses of MLN8237 based on a 3 + 3 design.